Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236023 | 0.92 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8148997 | 0.88 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13058977 | 0.85 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22472 | 0.83 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1286402 | 0.83 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24685887 | 0.81 | NQO1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12093386 | 0.81 | HTT (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19862416 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24305884 | 0.81 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12093570 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3315579-B1 | SURFACE TREATMENT AGENT INCLUDING PERFLUORO(POLY)ETHER GROUP-CONTAINING SILANE COMPOUND | DAIKIN IND LTD (JP) | 2024-05-01 | — | — | EP | claimed |
| EP-3088487-B1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | DAIKIN IND LTD (JP) | 2021-05-05 | — | — | EP | claimed |
| US-10781222-B2 | Surface treating agent including perfluoro(poly)ether-group-containing silane compound | DAIKIN INDUSTRIES, LTD. (JP) | 2020-09-22 | — | — | US | claimed |
| US-10703932-B2 | Surface treating agent including perfluoro(poly)ether-group-containing silane compound | DAIKIN INDUSTRIES, LTD. (JP) | 2020-07-07 | — | — | US | claimed |
| CN-107709506-B | Surface treating agent containing perfluoro (poly) ether group-containing silane compound | 大金工业株式会社 | 2020-06-16 | — | — | CN | claimed |
| US-20180186820-A1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3315579-A1 | SURFACE TREATMENT AGENT INCLUDING PERFLUORO(POLY)ETHER GROUP-CONTAINING SILANE COMPOUND | Daikin Industries, Ltd. (JP) | 2018-05-02 | — | — | EP | claimed |
| US-20160340544-A1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | claimed |
| EP-3088487-A1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | Daikin Industries, Ltd. (JP) | 2016-11-02 | — | — | EP | claimed |
| CN-105849222-A | Surface treating agent comprising perfluoro (poly) ether group-containing silane compound | 大金工业株式会社 | 2016-08-10 | — | — | CN | claimed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260007625-A1 | Compounds for the Treatment of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| EP-4587418-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-3315579-B1 | SURFACE TREATMENT AGENT INCLUDING PERFLUORO(POLY)ETHER GROUP-CONTAINING SILANE COMPOUND | DAIKIN IND LTD (JP) | 2024-05-01 | — | — | EP | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
| CN-1155279-A | Neuroprotective 3-(piperidinyl-1)-chroman-4,7,-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkane alcohol | PFIZER (US) | 1997-07-23 | — | — | CN | disclosed |
| EP-0777652-A1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996037226-A2 | COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS | PFIZER INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996006081-A1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007625-A1 | Compounds for the Treatment of Neuromuscular Disorders | RYR1, CACNB1, CACNA1S | CA12 2573/4885CA1 1053/4885CA2 262/4885 |
| US-20180186820-A1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | EPCAM, PFAS, SULT1A1 | CA12 602/4885CA1 1148/4885CA2 2120/4885 |
| US-10781222-B2 | Surface treating agent including perfluoro(poly)ether-group-containing silane compound | EPCAM, PFAS, SULT1A1 | CA12 602/4885CA1 1148/4885CA2 2120/4885 |
| US-10703932-B2 | Surface treating agent including perfluoro(poly)ether-group-containing silane compound | FRG1, AFF1, F11 | CA12 2012/4885CA1 1187/4885CA2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.